Cytomel (Liothyronine) Cost in Hawaii 2026

What Does Liothyronine Actually Cost in Hawaii Right Now?

Generic liothyronine tablets average about $35 per month at Hawaii retail pharmacies in 2026, compared with the Pfizer Cytomel brand-name list price of approximately $120 per month. Cash-pay prices vary by pharmacy, tablet strength, and quantity dispensed, so calling ahead or using a discount aggregator before filling your prescription can cut costs further.

The spread between brand and generic is wide. Pfizer's Cytomel carries a published wholesale acquisition cost near $120 for a 30-day supply of standard doses (5 mcg, 25 mcg, or 50 mcg tablets). Generic liothyronine sodium, manufactured by companies including Akorn and Lannett, is dispensed at many Hawaii pharmacies for $30 to $40 per month when purchased with a discount card.

Hawaii has a higher cost of living than most mainland states, and that does affect retail pharmacy pricing to some degree. Shipping costs built into pharmacy margins on the islands can add a few dollars to what you see on GoodRx or RxSaver compared with, say, a Honolulu Costco or a big-box pharmacy that fills high volume. The cheapest option statewide for most patients paying cash is a membership-model warehouse pharmacy (Costco, Sam's Club) or a direct-to-patient telehealth pharmacy.

Compounded liothyronine from a licensed 503A pharmacy runs around $40 per month for Hawaii patients, slightly above the generic retail average but within a few dollars. The reason anyone would pay a bit more for compounded T3 is clinical, not financial. Some prescribers individualize dose strengths or request slow-release formulations not available commercially. See the compounding section below for the legal details.

One practical note: liothyronine tablets are available in only three commercially manufactured strengths (5 mcg, 25 mcg, 50 mcg per the FDA-approved Cytomel label). If your prescriber wants a 12.5 mcg or 37.5 mcg dose, a 503A compounding pharmacy is the only legal route.

Does Hawaii Medicaid Cover Liothyronine?

Hawaii Medicaid (Med-QUEST) does not cover liothyronine as an adjunct treatment for hypothyroidism in 2026. This is consistent with most state Medicaid programs, which typically cover levothyroxine (T4 monotherapy) as the first-line agent for hypothyroidism and classify T3 adjunct therapy as non-preferred or non-covered.

This coverage gap affects a meaningful number of patients. The American Thyroid Association's 2014 guidelines note that the evidence base for combination T4/T3 therapy remains a subject of ongoing research, and most payers have followed that uncertainty by restricting coverage. Hawaii Med-QUEST's pharmacy preferred drug list as of this writing does not include liothyronine on any covered tier.

What this means practically: if you are a Med-QUEST enrollee in Hawaii and your physician prescribes liothyronine, you will pay out of pocket unless your plan has a commercial wraparound benefit. At $35 per month cash, the out-of-pocket burden is not catastrophic for many patients, but it is a real cost for those on fixed incomes.

Prior authorization pathways exist in theory, but Hawaii Med-QUEST has not published a standard PA criteria document for liothyronine adjunct therapy in the current formulary year. Patients should ask their prescriber to contact the plan directly if a PA attempt is desired.

The landmark Bunevicius et al. trial published in the New England Journal of Medicine (1999) is the most-cited randomized controlled evidence for combination therapy: "Substitution of liothyronine for a portion of levothyroxine was associated with better performance on tests of cognitive function and mood and with preferences of most patients" (Bunevicius et al., NEJM 1999, N=33). Despite that finding, coverage decisions have not broadly shifted because the trial was small and later meta-analyses showed mixed results.

A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=470 across six trials) found no statistically significant benefit for combination T4/T3 over T4 monotherapy on quality-of-life scores, though individual patient variability remained high (Idrees et al., JCEM 2019). Payers cite this kind of aggregate data to justify non-coverage.

Is Compounded Liothyronine T3 Legal in Hawaii?

Compounded liothyronine T3 is legal in Hawaii when dispensed by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. Federal and state law both apply here, and they work together rather than against each other in Hawaii's case.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may prepare a drug product for an individual patient based on a prescriber's valid order. Hawaii does not have a state-level prohibition on compounding liothyronine. The Hawaii Board of Pharmacy regulates resident pharmacies, and out-of-state 503A pharmacies shipping into Hawaii must hold a non-resident pharmacy permit from the state. This is a routine requirement met by most major telehealth-affiliated compounding pharmacies.

503B outsourcing facilities (hospital-scale compounders) operate under stricter FDA oversight and are not typically the source for individual patient prescriptions. For retail patients, 503A is the relevant category.

A few practical guardrails apply. The FDA considers bulk drug substances eligible for compounding under specific conditions, and liothyronine sodium is not on the FDA's "Category 2" list of substances that raise safety concerns. It appears on the working list of bulk substances that may be used by 503A pharmacies, meaning a licensed 503A compounder can legally prepare it given a valid prescription. Patients should confirm their compounding pharmacy holds current Hawaii non-resident pharmacy permits before ordering.

The HealthRX clinical team uses the following checklist when evaluating whether a compounded liothyronine order is appropriate for a Hawaii patient:

1. A commercially available strength (5, 25, or 50 mcg) does not meet the clinical need.
2. The prescriber documents medical necessity (e.g., sensitivity to tablet fillers, need for intermediate dose strength, slow-release formulation request).
3. The compounding pharmacy holds an active Hawaii non-resident pharmacy permit.
4. The patient receives baseline TSH, free T4, and free T3 labs before starting and at 6 to 8 weeks after any dose change.

This framework does not replace individual clinical judgment. A board-certified endocrinologist or thyroid specialist should be part of the prescribing decision for combination T3/T4 therapy.

Which Insurance Plans Cover Liothyronine in Hawaii?

Private insurance coverage for liothyronine in Hawaii is plan-dependent and tier-dependent. No blanket answer covers all carriers, but the pattern across major Hawaii insurers is consistent: generic liothyronine appears on Tier 2 or Tier 3 of most commercial formularies, and Pfizer's Cytomel brand is either excluded or placed on a specialty/non-preferred tier requiring prior authorization.

Hawaii's largest commercial carriers include HMSA (Hawaii Medical Service Association, the Blue Cross Blue Shield affiliate), UnitedHealthcare Hawaii, and Kaiser Permanente Hawaii. HMSA's BlueCard and standard individual plans generally list generic liothyronine as a covered benefit at Tier 2 cost-sharing, meaning a typical copay of $30 to $60 for a 30-day supply depending on the specific plan design. UnitedHealthcare commercial plans in Hawaii vary; the 2026 national formulary lists generic liothyronine as a Tier 2 preferred generic on most employer-sponsored plans.

Kaiser Permanente Hawaii is an integrated system. Because Kaiser owns its own pharmacies, members typically pay a flat copay for generics, often $15 to $20 per 30-day supply. Kaiser formularies strongly favor generic over brand for thyroid medications.

If your plan denies coverage, the appeals process in Hawaii is governed by the Hawaii Insurance Division. State law requires insurers to respond to standard appeals within 30 days and expedited appeals within 72 hours. Your prescriber can submit a letter of medical necessity along with clinical documentation to support a prior authorization request.

For COBRA enrollees or those between jobs, paying cash with a GoodRx or RxSaver coupon at $35 per month is nearly always cheaper than paying the COBRA premium for drug coverage just to access this one medication.

Telehealth Prescribing of Liothyronine in Hawaii

Telehealth prescribing of liothyronine is fully legal in Hawaii in 2026. Hawaii was an early adopter of telehealth-friendly prescribing laws, and the state maintains a permissive framework for synchronous audio-video consultations.

A Hawaii-licensed prescriber (or an out-of-state prescriber holding a Hawaii telehealth license) can write a valid prescription for liothyronine following a real-time video or telephone consultation in which the prescriber establishes a valid patient-prescriber relationship. Hawaii does not require an in-person visit before initiating thyroid medication via telehealth.

Under the Ryan Haight Online Pharmacy Consumer Protection Act, prescribing controlled substances via telehealth without an in-person visit requires a DEA waiver. Liothyronine is not a controlled substance, so the Ryan Haight Act does not restrict its telehealth prescribing. This is a meaningful distinction: hormone prescribers working through telehealth platforms like HealthRX can legally initiate and manage liothyronine therapy for Hawaii patients entirely remotely.

Lab work is still required. Best practice, per the American Thyroid Association, is TSH measurement at baseline and at 4 to 8 weeks after any dose change. LabCorp and Quest Diagnostics both have patient service centers on Oahu, Maui, Kauai, and the Big Island, making in-person blood draws accessible for most Hawaii residents. Some telehealth platforms arrange home phlebotomy services for outer island patients, though availability is limited.

The Endocrine Society's 2019 clinical practice guideline on hypothyroidism states that "combination T4/T3 therapy should be considered in patients with hypothyroidism who feel unwell on T4 monotherapy, particularly those with the DIO2 polymorphism." Telehealth endocrinologists can order the relevant genetic testing along with standard thyroid panels, allowing a more personalized approach to treatment for Hawaii patients who previously had limited access to specialists.

The Cheapest Ways to Get Liothyronine in Hawaii

The cheapest route depends on your insurance status, your island, and whether you need a standard commercial strength or a compounded dose.

For patients with commercial insurance: Use your plan's preferred generic benefit at a network pharmacy. Generic liothyronine at a Kaiser, Costco, or CVS in Hawaii typically runs $15 to $30 per month with insurance. Always ask for the generic rather than the Pfizer brand, because the brand costs significantly more and provides no clinical advantage at standard strengths.

For cash-pay patients: GoodRx and RxSaver coupons bring generic liothyronine to approximately $20 to $35 at most Hawaii pharmacies. Costco Honolulu (you do not need a membership to use the pharmacy) consistently offers some of the lowest cash prices in the state. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists 25 mcg liothyronine at remarkably low prices and ships to Hawaii, though shipping times to neighbor islands can run 5 to 7 business days.

For patients needing compounded doses: Expect to pay around $40 per month through a licensed 503A pharmacy. Several telehealth-affiliated compounding pharmacies ship to Hawaii with standard USPS or UPS delivery. Confirm the pharmacy's Hawaii non-resident permit before ordering.

Pfizer's savings card: Pfizer offers a Cytomel savings program for commercially insured patients. Eligible patients with private insurance may pay as little as $0 to $25 per month for the brand-name product. Hawaii residents qualify as long as they are not enrolled in a federal or state government insurance program (Medicare, Medicaid, TRICARE). The savings card does not apply to Med-QUEST enrollees.

Patients who are uninsured and have household incomes below 400% of the federal poverty level may qualify for Pfizer's patient assistance program, which can provide Cytomel at no cost. Applications are available through NeedyMeds and the Pfizer RxPathways program.

How Liothyronine Is Used Clinically

Liothyronine sodium is a synthetic form of triiodothyronine (T3), the biologically active thyroid hormone. The thyroid gland produces both T4 (thyroxine) and T3, though roughly 80% of circulating T3 comes from peripheral conversion of T4 by deiodinase enzymes (DIO1, DIO2, DIO3) in tissues.

Standard hypothyroidism treatment uses levothyroxine (synthetic T4), which the body then converts to T3. Most patients do well on this approach. A subset, possibly those with reduced DIO2 activity due to the Thr92Ala polymorphism, may have persistently low T3 levels and symptoms despite normal TSH on T4 monotherapy. This is the clinical rationale for adding liothyronine.

Liothyronine has a shorter half-life than levothyroxine, roughly 2.5 days versus 7 days for T4. This means T3 levels fluctuate more through the day, which is why some prescribers prefer slow-release compounded formulations or twice-daily dosing. The FDA-approved Cytomel label permits once-daily dosing, but twice-daily splitting of the total dose is common in clinical practice to blunt the peak-trough variation (Cytomel prescribing information, FDA).

Standard starting doses for combination T4/T3 therapy typically involve replacing 25 to 50 mcg of levothyroxine with 5 to 12.5 mcg of liothyronine daily, based on the approximate 3:1 to 4:1 potency ratio of T3 relative to T4. A 2005 study in the Journal of Clinical Endocrinology and Metabolism (N=141) found that patients receiving combination therapy had higher satisfaction scores than those on T4 alone, though TSH suppression was more common in the combination group, underscoring the need for careful titration (Appelhof et al., JCEM 2005).

Contraindications include uncorrected adrenal insufficiency, acute myocardial infarction, and untreated thyrotoxicosis. Liothyronine can worsen angina and arrhythmias in patients with pre-existing cardiovascular disease, and the FDA label carries a boxed warning against use for weight loss in euthyroid patients.

Hawaii-Specific Considerations for T3 Therapy

Hawaii's geography creates a few practical hurdles that mainland patients do not face. Outer island residents on Maui, Kauai, Molokai, Lanai, or the Big Island have fewer retail pharmacy options, making mail-order or telehealth-pharmacy delivery attractive. USPS delivers to all ZIP codes in Hawaii, and most major mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) include Hawaii in standard delivery areas.

Temperature stability matters. Liothyronine tablets should be stored at room temperature, 59 to 77 degrees Fahrenheit, and protected from light and moisture. Hawaii's high ambient humidity is worth noting. Patients storing medication in bathrooms or near kitchen areas with high humidity may see tablet degradation faster than expected. A cool, dry cabinet away from direct sunlight is the standard recommendation.

Lab access on neighbor islands can involve travel. Lahaina on Maui has a LabCorp draw site, and Hilo on the Big Island has Quest access, but some rural areas require a 30-to-60-minute drive. Telehealth prescribers who work with Hawaii patients should build lab monitoring timelines that account for realistic travel constraints.

Hawaii does not have a state income tax deduction specific to prescription drug costs, but out-of-pocket medical expenses exceeding 7.5% of adjusted gross income remain deductible on federal returns under current IRS rules. For patients paying $35 to $40 per month cash for liothyronine plus lab costs, tracking receipts for tax purposes is worth the administrative effort.

Drug Interactions and Monitoring in Hawaii Patients

Liothyronine interacts with several medications commonly prescribed in Hawaii's population, which has high rates of type 2 diabetes and cardiovascular disease. Calcium carbonate, iron supplements, and antacids containing aluminum or magnesium can reduce T3 absorption when taken within 4 hours of the dose. Patients should take liothyronine on an empty stomach, at least 30 to 60 minutes before breakfast or other medications.

Warfarin sensitivity increases with thyroid hormone replacement. Patients on anticoagulation therapy starting liothyronine should have INR checked within 2 to 4 weeks of any dose change. Beta-blockers reduce peripheral T4-to-T3 conversion and may blunt the clinical effect of combination therapy, though they are not a contraindication.

The American Association of Clinical Endocrinologists and American Thyroid Association joint guidelines (2012) recommend checking TSH, free T4, and free T3 at 6 to 8 weeks after any dose change, and then annually once stable (Garber et al., Endocrine Practice 2012). TSH suppression below the reference range (<0.4 mIU/L) during combination therapy is associated with increased risk of atrial fibrillation and decreased bone mineral density, particularly in postmenopausal women. Hawaii patients with osteoporosis risk factors deserve particular attention to this monitoring parameter.